{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:10:24Z","timestamp":1792887024362,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Penile squamous cell carcinoma (PSCC) is a highly aggressive malignancy with a poor prognosis. <jats:italic>BRCA1\/2<\/jats:italic> mutations are associated with impaired DNA double-strand break repair and are among the common mutations in penile cancer, potentially paving the way for poly ADP-ribose polymerase inhibitor therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a 65-year-old male with PSCC who progressed to thigh metastasis at 10\u00a0months after partial penectomy. Next-generation sequencing showed that the penis primary lesion and metastatic thigh lesion harboured a <jats:italic>BRCA2<\/jats:italic> mutation. Chemotherapy plus immunotherapy was used for treatment, and the thigh metastasis was found to involve no tumour. Progression-free survival (PFS) lasted for 8\u00a0months until the appearance of lung metastasis. Afterwards, the patient benefited from second-line therapy of olaparib with pembrolizumab and anlotinib, and his disease was stable for 9\u00a0months. The same <jats:italic>BRCA2<\/jats:italic> was identified in the lung biopsy. Given the tumour mutation burden (TMB, 13.97 mutation\/Mb), the patient received third-line therapy with nivolumab plus ipilimumab, but PFS only lasted for 3\u00a0months, with the appearance of right frontal brain metastasis. Then, the patient was treated with radiation sequential fluzoparib therapy as fourth-line treatment, and the treatment efficacy was evaluated as PR. Currently, this patient is still alive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first report of penile cancer with <jats:italic>BRCA2<\/jats:italic> mutation, receiving a combination treatment with olaparib and experiencing a benefit for 9\u00a0months. This case underscores the pivotal role of <jats:italic>BRCA2<\/jats:italic> in influencing treatment response in PSCC, providing valuable insights into the application of targeted therapies in managing recurrent PSCC with <jats:italic>BRCA2<\/jats:italic> alterations. This elucidation establishes a crucial foundation for further research and clinical considerations in similar cases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-024-03305-9","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:02:27Z","timestamp":1707454947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation"],"prefix":"10.1186","volume":"22","author":[{"given":"Qing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"3305_CR1","doi-asserted-by":"crossref","unstructured":"Wang Y, Wang, K, Chen, Y, Zhou, J, Liang, Y, Yang, X, et al, Mutational landscape of penile squamous cell carcinoma in a Chinese population. Int J Cancer. 2019;145:1280\u20139.","DOI":"10.1002\/ijc.32373"},{"key":"3305_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.urology.2013.08.074","volume":"83","author":"A Brown","year":"2014","unstructured":"Brown A, Ma Y, Danenberg K, et al. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014;83:159\u201365.","journal-title":"Urology"},{"key":"3305_CR3","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","volume":"81","author":"K Cong","year":"2021","unstructured":"Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021;81:3128-44.e7.","journal-title":"Mol Cell"},{"issue":"9","key":"3305_CR4","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-20-4004","volume":"27","author":"Jad Chahoud","year":"2021","unstructured":"Chahoud Jad, Gleber-Netto Frederico O, McCormick Barrett Z, Rao Priya, et al. Whole-exome sequencing in penile squamous cell carcinoma uncovers novel prognostic categorization and drug targets similar to head and neck squamous cell carcinoma. Clin Cancer Res. 2021;27(9):2560\u201370.","journal-title":"Clin Cancer Res"},{"key":"3305_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1634\/theoncologist.2015-0241","volume":"21","author":"SM Ali","year":"2016","unstructured":"Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, et al. Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations. Oncologist. 2016;21:33\u20139.","journal-title":"Oncologist"},{"key":"3305_CR6","unstructured":"FDA approves olaparib for adjuvant treatment of high-risk early breast cancer | FDA [WWW Document], n.d. URL https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer (accessed 12.7.22)."},{"key":"3305_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/COC.0b013e31817f9e1c","volume":"32","author":"A Fourquet","year":"2009","unstructured":"Fourquet A, Stoppa-Lyonnet D, Kirova YM, Sigal-Zafrani B, Asselain B. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1\/2 mutations status. Am J Clin Oncol. 2009;32:127\u201331.","journal-title":"Am J Clin Oncol"},{"key":"3305_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-16-0197","volume":"4","author":"L Galluzzi","year":"2016","unstructured":"Galluzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res. 2016;4:895\u2013902.","journal-title":"Cancer Immunol Res"},{"key":"3305_CR9","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"},{"key":"3305_CR10","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nsmb.2096","volume":"18","author":"WK Holloman","year":"2011","unstructured":"Holloman WK. Unraveling the mechanism of BRCA2 in homologous recombination. Nat Struct Mol Biol. 2011;18:748\u201354.","journal-title":"Nat Struct Mol Biol"},{"key":"3305_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.juro.2018.09.056","volume":"201","author":"JM Jacob","year":"2019","unstructured":"Jacob JM, Ferry EK, Gay LM, Elvin JA, Vergilio JA, Ramkissoon S, et al. Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy. J Urol. 2019;201:541\u20138.","journal-title":"J Urol"},{"key":"3305_CR12","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11:2983\u201394.","journal-title":"Acta Pharm Sin B"},{"key":"3305_CR13","doi-asserted-by":"publisher","first-page":"69105","DOI":"10.18632\/oncotarget.19079","volume":"8","author":"P Lesueur","year":"2017","unstructured":"Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, No\u00ebl G, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8:69105\u201324.","journal-title":"Oncotarget"},{"key":"3305_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.837547","volume":"12","author":"N Li","year":"2022","unstructured":"Li N, Xu T, Zhou Z, Li P, Jia G, Li X. Immunotherapy combined with chemotherapy for postoperative recurrent penile squamous cell carcinoma: a case report and literature review. Front Oncol. 2022;12: 837547.","journal-title":"Front Oncol"},{"key":"3305_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-82060-2_11","volume-title":"Management of metastatic penile cancer","author":"BA McGregor","year":"2021","unstructured":"McGregor BA, Sonpavde GP. Management of metastatic penile cancer. Cham: Springer International Publishing; 2021."},{"key":"3305_CR16","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","volume":"28","author":"LC Pagliaro","year":"2010","unstructured":"Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28:3851\u20137.","journal-title":"J Clin Oncol"},{"issue":"13","key":"3305_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.968163","volume":"13","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Zhao S, Wu T, Zhang H. Comparison of adverse reactions caused by olaparib for different indications. Front Pharmacol. 2022Jul;13(13): 968163.","journal-title":"Front Pharmacol"},{"key":"3305_CR18","doi-asserted-by":"crossref","unstructured":"Penile cancer. Nat Rev Dis Primers. 2021;7:12.","DOI":"10.1038\/s41572-021-00253-6"},{"key":"3305_CR19","doi-asserted-by":"publisher","first-page":"20170657","DOI":"10.1259\/bjr.20170657","volume":"92","author":"A Vallard","year":"2019","unstructured":"Vallard A, Magn\u00e9 N, Guy JB, Espenel S, Rancoule C, Diao P, et al. Is breast-conserving therapy adequate in BRCA 1\/2 mutation carriers? The radiation oncologist\u2019s point of view. Br J Radiol. 2019;92:20170657.","journal-title":"Br J Radiol"},{"key":"3305_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.urology.2014.12.049","volume":"85","author":"J Wang","year":"2015","unstructured":"Wang J, Pettaway CA, Pagliaro LC. Treatment for metastatic penile cancer after first-line chemotherapy failure: analysis of response and survival outcomes. Urology. 2015;85:1104\u201310.","journal-title":"Urology"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03305-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:02:36Z","timestamp":1707454956000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03305-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3305"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03305-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}